The shape of the weight loss curve
Slow start, steep middle, gradual plateau. This is the average curve from STEP 1 trial.
Milestones: real pounds at each point
Averages from trial data. Individual results vary, but these give you a realistic picture of what to expect.
| Time | % of body weight | 200 lb person | 250 lb person |
|---|---|---|---|
| 1 month | ~2% | ~4 lbs | ~5 lbs |
| 3 months | ~7% | ~14 lbs | ~17 lbs |
| 6 months | ~12% | ~24 lbs | ~30 lbs |
| 9 months | ~14% | ~28 lbs | ~35 lbs |
| 12 months | ~14.9% | ~30 lbs | ~37 lbs |
| 2 years | ~15% (maintained) | ~30 lbs | ~37 lbs |
The four phases of the year
Knowing where you are in the arc helps you manage expectations — and stops you from panicking when the scale stalls.
The slow start
- Typical loss: 2–5 lbs
- You are still titrating up — the dose is not yet clinically active
- Appetite starts to shift, food noise may quieten
- Side effects (nausea, fatigue) often peak here
- Do not measure success yet
The steep descent
- The fastest phase — most of your total loss happens here
- You have reached a clinically active dose
- Typical loss: 1.5–2.5 lbs per week on average
- Scale drops are less linear — some flat weeks are normal
- This is when clothes start fitting differently
The slow burn
- Loss slows to 0.5–1 lb per week on average
- You are chasing the last few percentage points
- Resistance training and protein become more important
- Small plateaus (1–3 weeks of no movement) are normal
- Your maintenance identity starts to form
The plateau
- Weight stabilises — this is the new set point, not failure
- Your body has adapted to a lower energy state
- Staying on treatment keeps the weight off
- Stopping typically means regaining 50–70% within a year
- Long-term: most people maintain their loss on-drug
The first month: managing expectations
Why the first few weeks feel like nothing
You are on the starting dose. That dose is not designed to cause weight loss — it is designed to let your gut adapt to the drug so you do not vomit for a week straight. Weight loss really begins when you reach the first clinically active dose, which is 4–12 weeks in depending on the drug.
The scale may still move 2–5 lbs in the first month, mostly from appetite reduction and water weight. That is normal and expected. The steep part of the curve comes later.
Not everyone gets the average
Trial averages hide a wide range. Here is how participants were distributed at 68–72 weeks.
Strong responders
~32%
Average responders
~69%
Modest responders
~87%
Percentages overlap — a "10% responder" is also counted in the "5% responder" group.
Hitting the plateau
Plateauing is not the same as failing
When you stop losing weight around month 12, the drug has not stopped working. Your body has adapted. At lower body weight, you burn fewer calories at rest — a 200-lb body does not need the same fuel as a 250-lb body. The plateau is where the drug's appetite suppression now matches your new maintenance needs. If staying on treatment keeps you at your new weight, that is success, not failure.
Common questions
Written and maintained by one person · Built with agentic AI tools · Every number checked against the cited trial · Not medical advice
Clinical trial data for Semaglutide
- STEP 1 — Semaglutide (injection): 1,961 adults with obesity or overweight with comorbidities, no type 2 diabetes, 68 weeks. New England Journal of Medicine, 2021. View source ↗
- STEP 2 — Adults with obesity and type 2 diabetes, 68 weeks. New England Journal of Medicine, 2021 View source ↗
- STEP 5 — Adults with obesity or overweight with comorbidities, no type 2 diabetes, 104 weeks (2 years). Nature Medicine, 2022 View source ↗
- OASIS 4 (oral semaglutide 25mg) — 307 adults with obesity or overweight + ≥1 comorbidity, 64 weeks. New England Journal of Medicine, 2024 View source ↗
- SELECT (cardiovascular outcomes) — 17,604 adults with established cardiovascular disease and overweight or obesity (BMI 27 or higher), without type 2 diabetes, ~40 months (median). New England Journal of Medicine, 2023 View source ↗
- Wegovy (semaglutide) tablets — FDA prescribing information — Oral semaglutide 25mg tablet-treated patients vs. placebo, OASIS 4 trial population, 68 weeks. FDA prescribing information (DailyMed), 2025 View source ↗
Keep reading
Next step most people take
Built with agentic AI tools and not a substitute for medical advice
Last reviewed: